Plaintiff
6 cases as plaintiff.
Regeneron Pharmaceuticals, Inc. is a public biotechnology company founded in 1988 and headquartered in Tarrytown, New York. Trading on the NASDAQ under the ticker REGN, the company has a market capitalization of approximately $74 billion as of April 2026 and employs over 15,000 people. For the twelve months ending in March 2026, Regeneron reported revenue of approximately $14.9 billion.
The company discovers, develops, and commercializes medicines for serious diseases. Its major products include Eylea and Eylea HD for eye disorders, Dupixent for allergic and inflammatory diseases, and the cancer immunotherapy Libtayo. Regeneron's research and development process relies heavily on its proprietary VelociSuite® technologies, which are used to produce fully human antibodies for potential drug candidates. The company's pipeline targets a range of therapeutic areas, including oncology, immunology, and rare diseases.
Regeneron's patent litigation posture is that of an operating company defending its key products from competitors. The provided case list shows the company exclusively as a defendant (two cases) and never as a plaintiff, which is typical for an innovative pharmaceutical firm facing challenges from generic or biosimilar manufacturers. Both tracked cases are proceedings before the Patent Trial and Appeal Board (PTAB), a common venue for patent validity challenges.
The notable cases reflect this defensive posture, as they involve biosimilar developers challenging patents for Regeneron's blockbuster drug, Eylea. Both Biocon Biologics, Inc. and Alvotech have filed petitions at the PTAB to invalidate patents related to Eylea and its high-dose formulation. This litigation is part of a broader, multi-front effort by Regeneron to defend the intellectual property of its highest-revenue product against numerous potential competitors seeking to launch their own versions.
Watchlist
Email-only, free, anonymous. We'll notify you when Regeneron Pharmaceuticals, Inc. files another patent-infringement lawsuit. One-click unsubscribe from any alert.
Regeneron sued Amgen for infringement of US Patent 11084865. The district court denied Regeneron's preliminary injunction request, a decision upheld by the Federal Circuit (CAFC Appeal No. 24-2351), leading Amgen to launch its biosimilar at-risk.
Regeneron sued Samsung Bioepis for infringement of US Patent 11084865. The district court granted a preliminary injunction, which the Federal Circuit affirmed. A related IPR challenge (IPR2025-00176) at the PTAB was denied institution.
Regeneron sued Formycon for infringement of US Patent 11084865. The district court granted a preliminary injunction, which the Federal Circuit affirmed. A related IPR challenge (IPR2025-00233) at the PTAB was denied institution.
Regeneron sued Celltrion for infringement of US Patent 11084865. The district court granted a preliminary injunction, which the Federal Circuit affirmed. A related IPR challenge (IPR2025-00456) at the PTAB was denied institution.
Regeneron secured a district court victory finding Mylan infringed US Patent 11084865. A subsequent settlement between Regeneron and Biocon (Mylan's associate) led to the dismissal of the district court case and a related Federal Circuit appeal (CAFC Appeal No. 24-2002), allowing commercialization of Mylan's biosimilar in 2026.
Regeneron initiated litigation against Sandoz concerning US Patent 11084865. The case is ongoing, following the approval of Sandoz's biosimilar in August 2024.